325 related articles for article (PubMed ID: 31382960)
21. Mapping the EORTC QLQ-C30 onto the EQ-5D-3L: assessing the external validity of existing mapping algorithms.
Doble B; Lorgelly P
Qual Life Res; 2016 Apr; 25(4):891-911. PubMed ID: 26391884
[TBL] [Abstract][Full Text] [Related]
22. Quantifying the Relationship between Capability and Health in Older People: Can't Map, Won't Map.
Franklin M; Payne K; Elliott RA
Med Decis Making; 2018 Jan; 38(1):79-94. PubMed ID: 29056069
[TBL] [Abstract][Full Text] [Related]
23. EQ-5D-5L and SF-6D Utility Measures in Symptomatic benign Thyroid Nodules: Acceptability and Psychometric Evaluation.
Wong CKH; Lang BHH; Yu HMS; Lam CLK
Patient; 2017 Aug; 10(4):447-454. PubMed ID: 28224296
[TBL] [Abstract][Full Text] [Related]
24. Differences in utility scores obtained through Brazilian and UK value sets: a cross-sectional study.
Takemoto ML; Lopes da Silva N; Ribeiro-Pereira AC; Schilithz AO; Suzuki C
Health Qual Life Outcomes; 2015 Aug; 13():119. PubMed ID: 26246238
[TBL] [Abstract][Full Text] [Related]
25. Mapping of the Gastrointestinal Short Form Questionnaire (GSF-Q) into EQ-5D-3L and SF-6D in patients with gastroesophageal reflux disease.
Monroy M; Ruiz MA; Rejas J; Soto J
Health Qual Life Outcomes; 2018 Sep; 16(1):177. PubMed ID: 30200982
[TBL] [Abstract][Full Text] [Related]
26. Are condition-specific utilities more valid than generic preference-based ones in asthma? Evidence from a study comparing EQ-5D-3L and SF-6D with AQL-5D.
Kontodimopoulos N; Stamatopoulou E; Brinia A; Talias MA; Ferreira LN
Expert Rev Pharmacoecon Outcomes Res; 2018 Dec; 18(6):667-675. PubMed ID: 30048194
[TBL] [Abstract][Full Text] [Related]
27. Generating EQ-5D-3L Utility Scores from the Dermatology Life Quality Index: A Mapping Study in Patients with Psoriasis.
Davison NJ; Thompson AJ; Turner AJ; Longworth L; McElhone K; Griffiths CEM; Payne K;
Value Health; 2018 Aug; 21(8):1010-1018. PubMed ID: 30098665
[TBL] [Abstract][Full Text] [Related]
28. A Quality-Adjusted Life-Year Measure for Multiple Sclerosis: Developing a Patient-Reported Health State Classification System for a Multiple Sclerosis-Specific Preference-Based Measure.
Goodwin E; Green C
Value Health; 2015 Dec; 18(8):1016-24. PubMed ID: 26686786
[TBL] [Abstract][Full Text] [Related]
29. Mapping the FACT-B Instrument to EQ-5D-3L in Patients with Breast Cancer Using Adjusted Limited Dependent Variable Mixture Models versus Response Mapping.
Gray LA; Wailoo AJ; Hernandez Alava M
Value Health; 2018 Dec; 21(12):1399-1405. PubMed ID: 30502783
[TBL] [Abstract][Full Text] [Related]
30. A comparison of utility measurement using EQ-5D and SF-6D preference-based generic instruments in patients with rheumatoid arthritis.
Salaffi F; Carotti M; Ciapetti A; Gasparini S; Grassi W
Clin Exp Rheumatol; 2011; 29(4):661-71. PubMed ID: 21813061
[TBL] [Abstract][Full Text] [Related]
31. Validity and reliability of the Finnish version of the Multiple Sclerosis Impact Scale-29.
Rosti-Otajärvi E; Hämäläinen P; Wiksten A; Hakkarainen T; Ruutiainen J
Brain Behav; 2017 Jul; 7(7):e00725. PubMed ID: 28729932
[TBL] [Abstract][Full Text] [Related]
32. An Updated Systematic Review of Studies Mapping (or Cross-Walking) Measures of Health-Related Quality of Life to Generic Preference-Based Measures to Generate Utility Values.
Mukuria C; Rowen D; Harnan S; Rawdin A; Wong R; Ara R; Brazier J
Appl Health Econ Health Policy; 2019 Jun; 17(3):295-313. PubMed ID: 30945127
[TBL] [Abstract][Full Text] [Related]
33. "Fibromyalgia and quality of life: mapping the revised fibromyalgia impact questionnaire to the preference-based instruments".
Collado-Mateo D; Chen G; Garcia-Gordillo MA; Iezzi A; Adsuar JC; Olivares PR; Gusi N
Health Qual Life Outcomes; 2017 May; 15(1):114. PubMed ID: 28558703
[TBL] [Abstract][Full Text] [Related]
34. Parallel Valuation: A Direct Comparison of EQ-5D-3L and EQ-5D-5L Societal Value Sets.
Law EH; Pickard AS; Xie F; Walton SM; Lee TA; Schwartz A
Med Decis Making; 2018 Nov; 38(8):968-982. PubMed ID: 30403577
[TBL] [Abstract][Full Text] [Related]
35. Mapping the Positive and Negative Syndrome Scale scores to EQ-5D-5L and SF-6D utility scores in patients with schizophrenia.
Abdin E; Chong SA; Seow E; Verma S; Tan KB; Subramaniam M
Qual Life Res; 2019 Jan; 28(1):177-186. PubMed ID: 30382480
[TBL] [Abstract][Full Text] [Related]
36. Mapping the EORTC QLQ-C30 to EQ-5D-3L in patients with breast cancer.
Gray LA; Hernandez Alava M; Wailoo AJ
BMC Cancer; 2021 Nov; 21(1):1237. PubMed ID: 34794404
[TBL] [Abstract][Full Text] [Related]
37. VALIDATION AND COMPARISON OF EQ-5D-3L AND SF-6D INSTRUMENTS IN A SPANISH PARKINSON´S DISEASE POPULATION SAMPLE.
Garcia-Gordillo MÁ; Del Pozo-Cruz B; Adsuar JC; Cordero-Ferrera JM; Abellan-Perpiñan JM; Sanchez-Martinez FI
Nutr Hosp; 2015 Dec; 32(6):2808-21. PubMed ID: 26667738
[TBL] [Abstract][Full Text] [Related]
38. Converting Parkinson-Specific Scores into Health State Utilities to Assess Cost-Utility Analysis.
Chen G; Garcia-Gordillo MA; Collado-Mateo D; Del Pozo-Cruz B; Adsuar JC; Cordero-Ferrera JM; Abellán-Perpiñán JM; Sánchez-Martínez FI
Patient; 2018 Dec; 11(6):665-675. PubMed ID: 29876865
[TBL] [Abstract][Full Text] [Related]
39. Association between Disability, Cognition, Fatigue, EQ-5D-3L Domains, and Utilities Estimated with Different Western European Value Sets in Patients with Multiple Sclerosis.
Eriksson J; Kobelt G; Gannedahl M; Berg J
Value Health; 2019 Feb; 22(2):231-238. PubMed ID: 30711069
[TBL] [Abstract][Full Text] [Related]
40. Mapping the cancer-specific QLQ-C30 onto the generic EQ-5D-5L and SF-6D in colorectal cancer patients.
Ameri H; Yousefi M; Yaseri M; Nahvijou A; Arab M; Akbari Sari A
Expert Rev Pharmacoecon Outcomes Res; 2019 Feb; 19(1):89-96. PubMed ID: 30173585
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
